Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurence Collette

Showing results (1-10 of 155) with videos related to

Pageof 16
Sort By:
European Urology|February 12, 2009
Re: Design and endpoints of clinical trials in patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working GroupLaurence Collette
European Urology|September 4, 2007
Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trialsLaurence Collette
The Journal of Urology|October 20, 2009
Editorial commentLaurence Collette
Nature Reviews. Urology|August 7, 2009
pT3N0M0 prostate cancer: a plea for adjuvant radiationMichel Bolla, Laurence Collette
The Lancet. Oncology|August 8, 2015
N-of-1 trials in oncologyLaurence Collette, Bertrand Tombal
Lancet (London, England)|April 2, 2013
Postoperative radiotherapy for high-risk prostate cancer - Authors' replyMichel Bolla, Laurence Collette
European Urology|June 24, 2010
Robot-assisted cystectomy: does it meet expectations?Urs E Studer, Laurence Collette
The Lancet. Oncology|May 9, 2014
Adjuvant chemotherapy for rectal cancer--authors' replyJean-François Bosset, Laurence Collette
European Urology|September 8, 2006
Morbidity from pelvic lymphadenectomy in men undergoing radical prostatectomyUrs E Studer, Laurence Collette
Nature Reviews. Urology|June 6, 2009
Prostate cancer: to screen or not to screen?Urs E Studer, Laurence Collette
Pageof 16

Showing results (1-10 of 155) with videos related to

Sort By:
Pageof 16
European Urology|February 12, 2009
Re: Design and endpoints of clinical trials in patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working GroupLaurence Collette
European Urology|September 4, 2007
Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trialsLaurence Collette
The Journal of Urology|October 20, 2009
Editorial commentLaurence Collette
Nature Reviews. Urology|August 7, 2009
pT3N0M0 prostate cancer: a plea for adjuvant radiationMichel Bolla, Laurence Collette
The Lancet. Oncology|August 8, 2015
N-of-1 trials in oncologyLaurence Collette, Bertrand Tombal
Lancet (London, England)|April 2, 2013
Postoperative radiotherapy for high-risk prostate cancer - Authors' replyMichel Bolla, Laurence Collette
European Urology|June 24, 2010
Robot-assisted cystectomy: does it meet expectations?Urs E Studer, Laurence Collette
The Lancet. Oncology|May 9, 2014
Adjuvant chemotherapy for rectal cancer--authors' replyJean-François Bosset, Laurence Collette
European Urology|September 8, 2006
Morbidity from pelvic lymphadenectomy in men undergoing radical prostatectomyUrs E Studer, Laurence Collette
Nature Reviews. Urology|June 6, 2009
Prostate cancer: to screen or not to screen?Urs E Studer, Laurence Collette
Pageof 16